Researchers at the Icahn School of Medicine at Mount Sinai have developed a new manufacturing platform for producing targeted mixtures of beneficial gut bacteria, an approach that could help expand access to microbiome-based therapies for patients with recurrent Clostridioides difficile (C. difficile) infection.
To continue reading click here
